Verdélite Sciences, Emerald Health Therapeutics’ wholly-owned subsidiary, Launches Souvenir™ Cannabis Brand in Québec
2020年6月23日 - 7:02PM
Verdélite Sciences (“Verdélite”) introduced its new Souvenir
Cannabis brand to the Québec adult-use recreational cannabis market
on June 22nd, 2020. The blue and white packaging marked with the
Fleur-de-lys shows Verdélite’s commitment to the Quebec market.
Verdélite is a vertically integrated 88,000 square foot indoor
growing facility outside Montreal in St. Eustache with 67 full-time
employees. The staff embody over 80 years of Québec growing
experience, which is evident in the quality of the Souvenir craft
batches.
“We are thrilled to bring Souvenir into the
adult recreational cannabis market in Québec, especially in time
for St. Jean-Baptiste Day. The team at Verdélite has poured heart
and soul into this launch, perfecting growing methods and bringing
the brand concept to life. We look forward to continuing our
relationship with the SQDC and providing Québec with great
cannabis.” – Maheep Dhillon, VP General Manager, Verdélite.
The Souvenir brand is exclusively sold through
the Société Québécoise du Cannabis (SQDC) where it will be
distributed throughout SQDC retail stores and on the SQDC online
store. With 42 stores today, the SQDC has plans to scale up to 70
stores by year-end with the intention to further combat the
cannabis black market and grow legal sales.
Souvenir is focused on bringing unique offerings
to the Québec market at a competitive price point. Every batch of
dried flower is hang-dried and cured to optimize terpene profiles
and, once hand-packaged, promptly deliver to the SQDC within weeks
to maintain freshness. With an extensive library of cannabis
genetics and ongoing R&D to develop different strains, Souvenir
aims to produce new flower selections every season.
The initial products included in the launch are
Chemdog and Grapefruit GG4, both high potency THC strains with
distinct aromas and flavours. Chemdog is a classic Sativa-dominant
hybrid, bred in the 1970s. Grapefruit GG4 is a combination of
Grapefruit, a citrusy Sativa, and GG4, a member of the Indica GG
family. As Souvenir expands into the Québec market, consumers can
expect new formats and categories from this Québec-focused
company.
For more information on Verdélite Science Inc.,
visit https://verdelite.ca/en or contact Maheep Dhillon at (604)
431-8500 or at mdhillon@emeraldhealth.ca. For media inquiries
contact Karim Marier at (514) 706-0113 or at
karim@marigoldpr.com.
About Verdélite Sciences
Inc.
Verdélite is a premium craft cannabis operation
licensed for cultivation and processing in Saint-Eustache, Québec.
The 88,000 square foot indoor facility has 21 highly-controlled
grow rooms and 16 processing rooms. The facility is licensed to
cultivate, process, package and sell cannabis flower products. The
license also allows Verdélite to perform research and development.
Verdélite is focused on developing Souvenir™, a unique brand with a
Québec identity for the adult use cannabis consumer. Verdélite is a
wholly owned subsidiary of Emerald Health Therapeutics, Inc. (TSXV:
EMH; OCTQX: EMHTF).
Please visit www.emeraldhealth.ca for more
information or contact:
Jenn Hepburn, Chief Financial Officer
(800) 757 3536 Ext. #5
Emerald Investor Relations
(800) 757 3536 Ext. #5
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking
Statements: Certain statements made in this press release that are
not historical facts are forward-looking statements and are subject
to important risks, uncertainties and assumptions, both general and
specific, which give rise to the possibility that actual results or
events could differ materially from our expectations expressed in
or implied by such forward-looking statements.
We cannot guarantee that any forward-looking
statement will materialize, and readers are cautioned not to place
undue reliance on these forward-looking statements. These
forward-looking statements involve risks and uncertainties related
to, among other things, changes of law and regulations; changes of
government; failure to obtain regulatory approvals or permits;
failure to obtain necessary financing; results of production and
sale activities; results of scientific research; regulatory
changes; changes in prices and costs of inputs; demand for labour;
demand for products; failure of counter-parties to perform
contractual obligations; as well as the risk factors described in
Emerald’s annual information form and other regulatory filings. The
forward-looking statements contained in this press release
represent our expectations as of the date hereof. Forward-looking
statements are presented for the purpose of providing information
about management's current expectations and plans and allowing
investors and others to obtain a better understanding of our
anticipated operating environment. Readers are cautioned that such
information may not be appropriate for other purposes. Emerald
undertakes no obligations to update or revise such statements to
reflect new circumstances or unanticipated events as they occur,
unless required by applicable law.
Photos accompanying this announcement are available
at:https://www.globenewswire.com/NewsRoom/AttachmentNg/30e41a45-4305-4cee-a81c-8788d41cf048https://www.globenewswire.com/NewsRoom/AttachmentNg/1c8dde9e-2e75-4275-ab47-52c8761710e9
Emerald Health Therapeut... (TSXV:EMH)
過去 株価チャート
から 10 2024 まで 11 2024
Emerald Health Therapeut... (TSXV:EMH)
過去 株価チャート
から 11 2023 まで 11 2024